TY - JOUR
T1 - Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC Global follow-up protocol
T2 - a prospective cohort study
AU - Sechenov Stop COVID Research Team
AU - Osmanov, Ismail M.
AU - Spiridonova, Ekaterina
AU - Bobkova, Polina
AU - Gamirova, Aysylu
AU - Shikhaleva, Anastasia
AU - Andreeva, Margarita
AU - Blyuss, Oleg
AU - El-Taravi, Yasmin
AU - DunnGalvin, Audrey
AU - Comberiati, Pasquale
AU - Peroni, Diego G.
AU - Apfelbacher, Christian
AU - Genuneit, Jon
AU - Mazankova, Lyudmila
AU - Miroshina, Alexandra
AU - Chistyakova, Evgeniya
AU - Samitova, Elmira
AU - Borzakova, Svetlana
AU - Bondarenko, Elena
AU - Korsunskiy, Anatoliy A.
AU - Konova, Irina
AU - Hanson, Sarah Wulf
AU - Carson, Gail
AU - Sigfrid, Louise
AU - Scott, Janet T.
AU - Greenhawt, Matthew
AU - Whittaker, Elizabeth A.
AU - Garralda, Elena
AU - Swann, Olivia V.
AU - Buonsenso, Danilo
AU - Nicholls, Dasha E.
AU - Simpson, Frances
AU - Jones, Christina
AU - Semple, Malcolm G.
AU - Warner, John O.
AU - Vos, Theo
AU - Olliaro, Piero
AU - Munblit, Daniel
AU - Abdeeva, Elina
AU - Alekseeva, Nikol
AU - Bairashevskaia, Anastasiia
AU - Baimukhambetova, Dina
AU - Baziyants, Lusine
AU - Berbenyuk, Anna
AU - Bezbabicheva, Tatiana
AU - Chayka, Julia
AU - Deunezhewa, Salima
AU - Filippova, Yulia
AU - Gorina, Anastasia
AU - Gorlenko, Cyrill
N1 - Publisher Copyright:
© 2022 European Respiratory Society. All rights reserved.
PY - 2022/2/1
Y1 - 2022/2/1
N2 - Background The long-term sequelae of coronavirus disease 2019 (Covid-19) in children remain poorly characterised. This study aimed to assess long-term outcomes in children previously hospitalised with Covid-19 and associated risk factors. Methods This is a prospective cohort study of children (≤18 years old) admitted with confirmed Covid-19. Children admitted to the hospital between April 2, 2020 and August 26, 2020, were included. Telephone interview using the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Covid-19 Health and Wellbeing paediatric follow-up survey. Persistent symptoms (<5 months) were further categorised by system(s) involved. Findings 518 of 853 (61%) of eligible children were available for the follow-up assessment and included in the study. Median age was 10.4 years (IQR, 3-15.2) and 270 (52.1%) were girls; median follow-up since hospital discharge was 256 (223-271) days. At the time of the follow-up interview 126 (24.3%) participants reported persistent symptoms among which fatigue (53, 10.7%), sleep disturbance (36, 6.9%,) and sensory problems (29, 5.6%) were the most common. Multiple symptoms were experienced by 44 (8.4%) participants. Risk factors for persistent symptoms were: Older age "6-11 years" (odds ratio 2.74 (95% confidence interval 1.37 to 5.75) and "12-18 years" (2.68, 1.41 to 5.4); and a history of allergic diseases (1.67, 1.04 to 2.67). Interpretation A quarter of children experienced persistent symptoms months after hospitalization with acute covid-19 infection, with almost one in ten experiencing multi-system involvement. Older age and allergic diseases were associated with higher risk of persistent symptoms at follow-up.
AB - Background The long-term sequelae of coronavirus disease 2019 (Covid-19) in children remain poorly characterised. This study aimed to assess long-term outcomes in children previously hospitalised with Covid-19 and associated risk factors. Methods This is a prospective cohort study of children (≤18 years old) admitted with confirmed Covid-19. Children admitted to the hospital between April 2, 2020 and August 26, 2020, were included. Telephone interview using the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Covid-19 Health and Wellbeing paediatric follow-up survey. Persistent symptoms (<5 months) were further categorised by system(s) involved. Findings 518 of 853 (61%) of eligible children were available for the follow-up assessment and included in the study. Median age was 10.4 years (IQR, 3-15.2) and 270 (52.1%) were girls; median follow-up since hospital discharge was 256 (223-271) days. At the time of the follow-up interview 126 (24.3%) participants reported persistent symptoms among which fatigue (53, 10.7%), sleep disturbance (36, 6.9%,) and sensory problems (29, 5.6%) were the most common. Multiple symptoms were experienced by 44 (8.4%) participants. Risk factors for persistent symptoms were: Older age "6-11 years" (odds ratio 2.74 (95% confidence interval 1.37 to 5.75) and "12-18 years" (2.68, 1.41 to 5.4); and a history of allergic diseases (1.67, 1.04 to 2.67). Interpretation A quarter of children experienced persistent symptoms months after hospitalization with acute covid-19 infection, with almost one in ten experiencing multi-system involvement. Older age and allergic diseases were associated with higher risk of persistent symptoms at follow-up.
UR - https://www.scopus.com/pages/publications/85124051254
U2 - 10.1183/13993003.01341-2021
DO - 10.1183/13993003.01341-2021
M3 - Article
C2 - 34210789
AN - SCOPUS:85124051254
SN - 0903-1936
VL - 59
JO - European Respiratory Journal
JF - European Respiratory Journal
IS - 2
M1 - A8
ER -